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Summary
Several BRCA2 mutations are found to occur in geo-
graphically diverse breast and ovarian cancer families.
To investigate both mutation origin and mutation-spe-
cific phenotypes due to BRCA2, we constructed a hap-
lotype of 10 polymorphic short tandem-repeat (STR)
markers flanking the BRCA2 locus, in a set of 111 breast
or breast/ovarian cancer families selected for having one
of nine recurrent BRCA2mutations. Six of the individual
mutations are estimated to have arisen 400–2,000 years
ago. In particular, the 6174delT mutation, found in
∼1% of individuals of Ashkenazi Jewish ancestry, was
estimated to have arisen 29 generations ago (1-LOD
support interval 22–38). This is substantially more re-
cent than the estimated age of the BRCA1 185delAG
mutation (46 generations), derived from our analogous
study of BRCA1 mutations. In general, there was no
evidence of multiple origins of identical BRCA2 muta-
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tions. Our study data were consistent with the previous
report of a higher incidence of ovarian cancer in families
with mutations in a 3.3-kb region of exon 11 (the ovar-
ian cancer cluster region [OCCR]) ( ); but thatP  .10
higher incidence was not statistically significant. There
was significant evidence that age at diagnosis of breast
cancer varied by mutation ( ), although only 8%P ! .001
of the variance in age at diagnosis could be explained
by the specific mutation, and there was no evidence of
family-specific effects. When the age at diagnosis of the
breast cancer cases was examined by OCCR, cases as-
sociated with mutations in the OCCR had a significantly
older mean age at diagnosis than was seen in those out-
side this region (48 years vs. 42 years; ).P  .0005
Introduction
The isolation of BRCA1 (Miki et al. 1994) and BRCA2
(Wooster et al. 1995; Tavtigian et al. 1996), two genes
predisposing to early-onset breast cancer and ovarian
cancer, has resulted in rapid identification of a large
number of families with mutations in these genes (Breast
Cancer Information Core) (Couch et al. 1996b; Szabo
and King 1997). Although both genes exhibit a large
number of distinct mutations, several mutations have
been found to recur in a number of independently as-
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certained families of apparently diverse geographical or-
igin, as well as in families largely confined to a single
population.
Genes responsible for inherited cancer, likemany other
disease genes, have been associated with a wide diversity
of expression. This is seen not only in variability in the
age at diagnosis of cancer but also in the anatomical site
at which the tumor originates. More important, at least
from the clinical perspective, is the degree to which spe-
cific mutations and accompanying genetic backgrounds
influence the expression of BRCA2 in terms of site and
age at diagnosis. For BRCA2,Gayther et al. (1997) have
provided evidence that mutations in an ∼3.3-kb nucle-
otide region of exon 11 (denoted the “ovarian cancer-
cluster region” [OCCR]) are associated with a higher
incidence of ovarian cancer relative to breast cancer. In
that study, this was highly significant, with an ovarian:
breast cancer ratio of 11:45 inside, and 22:282 outside,
the OCCR. In the present studies, four of the mutations
examined were within the OCCR, whereas the other five
were outside this region. This allowed us to examine,
with the present data set, the OCCR hypothesis.
In a previous paper (Neuhausen et al. 1996b), we
analyzed six recurrent BRCA1 mutations for haplotype
conservation, over a 3-Mb segment containing the
BRCA1 gene, using nine STR markers. We also inves-
tigated the relationship between the position of the mu-
tation and the phenotype (in terms of both age at di-
agnosis of breast cancer and proportion of ovarian
cancer) of the families carrying each mutation. In the
present article, we have undertaken a similar study of
recurrent BRCA2 mutations, addressing both mutation
origin and the relationship between mutation and phe-
notype. To do this, we constructed a haplotype of 10
polymorphic STR markers flanking the BRCA2 locus in
a set of 111 families (selected to contain one of nine
BRCA2 mutations that had been identified a minimum
of three times) and analyzed the phenotype associated
with each mutation. For five mutations for which suf-
ficient haplotype data existed, we estimated the age of
the mutation, using a modified version of our mathe-
matical model developed for our BRCA1 analysis.
Subjects and Methods
Family Ascertainment
Families with one of the nine mutations were from 24
centers located in 13 countries in Europe and North
America. The families had been previously ascertained
for a variety of reasons, including research studies, di-
rected screening of case series of ovarian or male breast
cancer, or attendence at a cancer genetics clinic. Appro-
priate informed consent was obtained from all partici-
pants. When possible, pedigree information was ob-
tained, although, for several centers, no such history was
available and, for other centers, only a limited family
history could be obtained. All cases of breast and ovarian
cancer reported in the pedigree were included in the
study, with the exception of cases who were known to
not carry the BRCA2mutation segregating in the family.
No independent verification of diagnosis was obtained,
and, for a small proportion of cases, age at diagnosis
was not available.
Samples for the 982del4 mutation were from the
United States and France; those for 2041insA, fromGer-
many, Canada, and the United States; those for
3034del4, from Belgium, Canada, Spain, France, Swit-
zerland, Italy, and the United States; those for 4486delG,
from Sweden; those for 5573insA, from theNetherlands;
those for 6174delT, from Canada, France, Israel, Hun-
gary, Sweden, the United Kingdom, and the United
States; those for 6503delTT, from Belgium, the Neth-
erlands, Sweden, and the United Kingdom; those for
9254del5, from France and Spain; and, those for
9326insA, from Hungary, Sweden, and the United
Kingdom.
Genotyping of 13q Markers
Genotyping was performed at four centers. The fam-
ilies collected by the University of Washington in Seattle,
the National Institute of Oncology in Budapest, and the
Fundacion Jimenez Diaz in Madrid were genotyped in
their respective laboratories; all other families were ge-
notyped in the Genetic Epidemiology Laboratory at the
University of Utah. At all centers, the same five DNA
samples were used as controls, and a similar protocol
was followed. All 10 markers genotyped were STR loci
assayed by PCR, with standard procedures. All the re-
sults in the tables are from analyses of all 10 markers.
For all mutations except 6174delT, allele frequencies
used in the likelihood calculations were as reported in
Genome Database, from typings of ∼80 independent
CEPH chromosomes. For analysis of family samples of
Ashkenazi Jewish ancestry carrying the 6174delT mu-
tation, we estimated marker-allele frequencies from the
haplotype data of the non–mutation-bearing chromo-
somes. In all cases, allele sizes were matched according
to the genotype of CEPH reference individual 1347-02,
who was used as a control on each gel. The genetic map
assumed for the haplotype analyses was derived from
physical-mapping data (Couch et al. 1996a; S. L. Neu-
hausen, unpublished data), under the assumption that
. Note that this rate is higher than the1.5 cM  1 Mb
usual 1:1 ratio assumed as a genomewide average; this
was done to ensure that the total distance of the map
was in agreement with that of the published genetic map
(Dib et al. 1996). None of the markers were located
intragenic to BRCA2. The assumed map order and dis-
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Table 1
Summary of STRs Used in Haplotype Analysis
Marker
Position
(cM) No. of Alleles
Heterozygositya
(%)
Size (Frequency) of Common
Allele
(bp)
Genotype of 1347-02
(bp)
D13S290 2.70 6 46 176 (.71), 190 (.11), 188 (.11) 190/176
D13S1444 1.35 9 80 167 (.41), 169 (.24), 177 (.11) 177/167
D13S1700 1.20 18 89 308 (.12), 312 (.09), 258 (.09) 320/254
D13S260 1.00 9 78 163 (.41), 161 (.13), 171 (.09) 163/161
D13S1699 .72 6 67 150 (.54), 146 (.37) 156/146
D13S1698 .63 10 63 152 (.35), 154 (.30) 168/160
BRCA2 .0
D13S171 .60 6 72 241 (.32), 231 (.32), 227 (.25) 231/231
D13S1695 .96 11 79 245 (.37), 247 (.23) 249/235
D13S310 2.10 5 70 146 (.40), 144 (.24), 140 (.24) 146/146
D13S267 3.12 6 69 148 (.44), 160 (.29), 154 (.17) 160/148
a Determined from genotyping of 80–100 chromosomes.
tances and the descriptions of the markers used are given
in table 1.
When possible, haplotypes associated with each mu-
tation were inferred from multiple samples of related
individuals within each kindred known to have the same
mutation; otherwise, multilocus genotypes were com-
pared. When haplotypes could not be determined with
certainty, all possible haplotypes (to a maximum of 64)
consistent with the observed multilocus genotypes were
considered in the likelihood analysis, in a manner anal-
ogous to the phase calculations in multipoint linkage
analysis.
Analysis of Haplotype Data
The estimation of the age of the mutations was per-
formed by use of the same statistical model that had
been used in our previous analysis of BRCA1 (Neuhau-
sen et al. 1996b), with several minor modifications. In
brief, the joint likelihood of the BRCA2 haplotypes (or
all possible haplotypes from families with a given mu-
tation, relative to a presumed ancestral haplotype) is
written as a function of the recombination fraction be-
tween the disease and each marker; the number of gen-
erations, G, since the mutation arose; and the mutation
rate and allele frequencies at each marker locus. The
marker D13S1700 was assumed to have a higher mu-
tation rate (.01) than the other markers (.002 for a tetra-
nucleotide repeat and .0006 for a dinucleotide repeat),
on the basis of both the large number of alleles and the
observation of mutations within families. We also in-
cluded another parameter, mD, the proportion of families
with an independent mutation identical to that of the
presumed ancestral haplotype. This parameter is anal-
ogous to genetic heterogeneity in standard linkage anal-
ysis and can be estimated from the data.
The method of maximum likelihood was used to find
the value of G that, among families with identical mu-
tations, best fitted the pattern of haplotype sharing at
the 10 marker loci. Approximate support intervals for
the age of each mutation were calculated by finding the
value of G on either side of the most likely value that
had a x10-fold decrease in likelihood. A test for het-
erogeneity of mutation origin was performed by com-
paring the likelihood at the maximum-likelihood esti-
mates of G and mD with the analogous likelihood,
assuming . Each generation is estimated to be 20m  0D
years.
Analysis of Phenotype Data
For each mutation, the number of families with that
mutation, the number of female and male breast cancer
cases, and the number of ovarian cancer cases were tab-
ulated. To partially counter any effects of ascertainment
of those directed-screening cases of breast and ovarian
cancers, we also examined the data only in those families
in which there were at least three cases of cancer, where
a case is defined as a female breast cancer at age !60
years, an ovarian cancer, or a male breast cancer. In this
second tabulation, only cases of female breast cancer at
age !60 years were counted in the breast cancer results;
this was done in order to increase the probability that
they were associated with the BRCA2 mutation segre-
gating in the family.
To test for heterogeneity, in the proportion of affected
individuals who had ovarian cancer, as a function of
whether the mutation associated with a given family was
inside or outside the hypothesized OCCR, a randomi-
zation test was performed. Specifically, random per-
mutations of families with the nine mutations were per-
formed, in which the number of families with each
mutation was kept equal to that present in the actual
data set. After this permutation step, the mutations were
grouped according to their location respective to the
OCCR. Each such permutation resulted in a different
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Table 2
Results of Haplotype Analysis of Nine Mutations
MUTATION
NO. OF
FAMI-
LIESa
NO. OF
COUNTRIESb
CORE HAPLOTYPE AT
CONSISTENCY
INDEXc G
1LOD
INTERVALD13S260 D13S1699 D13S1698 D13S171 D13S1695
982del4 5 (3/2) 2 161 146 154 231 253 5/5 18 (4–43)
2034insA 5 (3/2) 3 163 150 166 241 247 3/5 36 (13–64)
3034del4 11 (4/7) 7 163 146 154 227 245 2/11 80 (46–134)
4484delG 4 (0/4) 1 169 156 166 241 247 4/4 Not calculated
5573insA 3 (3/0) 1 165 146 154 227 245 2/3 Not calculated
6174delT 69 (22/47) 7 161 146 152 239 251 45/69 29 (22–38)
6503delTT 7 (5/2) 4 163 150 158 227 245 3/5 52 (24–98)
9254del5 3 (2/1) 2 163 150 154 231 X 2/3 Not calculated
9326insA 4 (1/3) 3 171 152 152 231 245 2/4 Not calculated
a Data in parentheses are number of families in which haplotypes could be determined/number of families for which only multilocus genotype
data were available.
b For names of countries, see the Subjects and Methods section.
c Number of samples/families consistent with core haplotype for all five markers listed.
2#2 table with an associated x2 statistic calculated in
the standard fashion. The x2 statistic associated with the
observed aggregation of cases and mutations was com-
pared with those calculated from 2,000 random per-
mutations of families and mutations. The rank of the
observed x2 statistic among those from 2,000 replicates
is the nominal P for testing the association between the
prevalence of ovarian cancer and a specific mutation.
The S-Plus package (StatSci) was used to perform the
randomization test. Phenotypic analysis of age at diag-
nosis, among mutations, was performed by the T-TEST,
GLM, and VARCOMP procedures of the SAS statistical
analysis package.
Results
Haplotype Analysis and Age of Mutations
The mutations described in this report span the
BRCA2 gene and are small insertions or deletions that
cause protein truncation. In table 2, the mutations are
characterized as to the number of families studied, the
numbers of genotypes and haplotypes obtained, and the
geographic diversity (as based on the number of coun-
tries from which samples were contributed). The most
common haplotype associated with each of the nine mu-
tations studied, as well as the estimated G, support in-
terval, and estimated heterogeneity for those mutations
with at least five haplotypes to analyze are also shown
in table 2. Although the estimation of the ages of the
mutations incorporated data from all 10 markers, we
report the consensus haplotype at the six markers closest
to BRCA2, since, in many cases, the haplotype beyond
these markers was difficult to determine. For four of the
five mutations examined, the estimated fraction of fam-
ilies in which cancer was due to an independent muta-
tional event was 0; for 6503delTT, the estimated pro-
portion was .11, which is not significantly different from
0. For 6174delT, the 1-LOD upper bound for the pro-
portion attributable to one (or more) independent iden-
tical mutations was .06. In all cases, there was no sig-
nificant evidence of mutational heterogeneity, indicating
that, for each mutation studied, all families with the
mutation represent derivations from a single ancestral
haplotype on which the mutation arose. The estimates
of G are based on assumptions about mutation rates
and recombination rates and therefore may be more ap-
propriately considered as relative indications of time
since the mutation originated, rather than as absolute
values. We estimate the 982del4, as an example, to have
occurred relatively recently—that is, 18 generations ago
(1-LOD support interval 4–43), or ∼360 years ago (1-
LOD support interval 80-860 years).
Association between Phenotypic Variation and
Mutations
A summary of the number of cases of breast and ovar-
ian cancers and the ages at diagnosis of the breast cancer
cases, stratified by BRCA2 mutation type, is shown in
table 3, for all families with all breast cancer cases and
for those “high-risk” families (as described in the Sub-
jects and Methods section) that have breast cancer cases
diagnosed at age !60 years. There was significant var-
iation in age at diagnosis among the nine mutations
tested when all cases in all families were considered
( , by nested ANOVA), as well as when theP  .0007
analysis was restricted to high-risk families and cases
diagnosed at age !60 years ( ), although onlyP  .015
∼8% and ∼6%, respectively, of the variance was ex-
plained by individual mutation. In both analyses, there
was no evidence of significant variation between fami-
lies, for any mutation group, and the variance due to
this effect was estimated to be zero in both cases.
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Table 3
Summary of Phenotypic Data Associated with Mutation
MUTATION
ALL FAMILIESa FAMILIES WITH x3 CASESb
No.
No. of Cancer Cases
No.
No. of Cancer Cases
Female Breast
(Age [years]) Ovarian Male Breast
Female Breast at Age
!60 Years (Age [years]) Ovarian Male Breast
982del4 5 25 (41) 1 4 4 20 (38) 1 4
2041insA 5 16 (41) 4 5 4 11 (39) 3 5
3034del4 11 37 (42) 6 2 9 33 (42) 5 2
4486delG 5 16 (48) 0 3 1 6 (44) 0 0
5573insA 3 5 (47) 7 0 2 2 (40) 7 0
6174delTc 67 119 (49) 29 12 22 60 (46) 12 8
6503delTT 7 20 (44) 12 1 6 18 (44) 12 1
9254del5 3 16 (48) 3 3 3 11 (43) 3 3
9326insA 4 9 (34) 0 2 1 3 (35) 0 1
Total 110 263 (45.6) 62 32 52 164 (42.7) 43 24
a Includes all families on which at least some phenotypic information was available. Breast cancer tabulation contains all
cases of breast cancer, regardless of age, as well as those cases for which age at diagnosis is unknown.
b Families with at least three cases of cancer, where a case is defined as a female breast cancer at age !60 years, an ovarian
cancer, or a male breast cancer. Only the cases of female breast cancer at age !60 years are included in the results.
c In 13 families obtained from a consecutive series of Ashkenazi Jewish ovarian cancer patients tested only for the 6174delT
mutation, the ovarian cancer proband was omitted from this table and subsequent analyses; however, the proband was used
in determining whether the family had three or more cases.
Examination of the OCCR
The randomization test described in the Subjects and
Methods section was used to examine possible differ-
ences in the relative proportions of cases of breast and
ovarian cancers, for mutations inside and outside the
OCCR. These results are shown in table 4. It is clear
that there is a higher proportion of ovarian cancer cases
associated with families with mutations in the OCCR
region, although this difference is not significant for ei-
ther the complete data set ( ) or the high-riskP  .12
subset ( ). The odds ratio for the entire set ofP  .11
families is 2.1. Interestingly, when we examined the age
at diagnosis of the breast cancer cases in terms of OCCR
status, we found that most of the age-at-onset variation
between mutations could be ascribed to the location rel-
ative to the OCCR. This difference, of older age at onset
for the OCCR region, was highly significant, both for
the nested analysis of variance with between-family var-
iation used as the error term and by ordinary t-test.
Because the 6174delT mutation group was the largest
and had the oldest age at onset, we also performed the
analysis of age at onset and OCCR again, without this
group. When we removed the cases with a 6174delT
mutation, the effect of the mutation location in the
OCCR is still present but is not significant ( ).P  .09
Discussion
In this paper, we have analyzed genotypic and phe-
notypic data from a series of breast cancer families and
from isolated cases with one of nine recurrent mutations
in the BRCA2 gene. These data appear to include both
population-specific sequence variants, as well as those
found in more geographically diverse populations of
northern European Caucasian ancestry. The mutation
with the oldest estimated age, 3034del4, was found in
the most diverse set of samples (except for the 6174delT
mutation in the Ashkenazi population), both in multiple
centers in the same country and in seven different coun-
tries. For the mutations studied, the multiple instances
of specific mutations generally appear to represent foun-
der effects many generations in the past, rather than
independent mutational events. This is in contrast to
the BRCA1 mutations—4184del4, Arg1443ter, and
185delAG—which, on the basis of the multiple origins
of these mutations, may represent hot spots (Neuhausen
et al. 1996b).
The 4486delG mutation has been reported only in
Scandanavia (Ha˚kansson et al. 1997). For this study,
there were too few haplotypes to determine the age of
the mutation. However, all four samples (three from spo-
radic male breast cancer cases and one large breast can-
cer family) genotyped with this mutation appeared to
share a conserved haplotype over an ∼3-cM interval con-
taining theBRCA2 locus. A similar patternwas observed
in the three Dutch families carrying the 5573insA mu-
tation. The 9254del5 mutation has been identified only
in two French families of Catalan origin and in a single
Spanish family also from this region. The three families
share a conserved haplotype over an ∼2-cM region span-
ning the BRCA2 locus. These three families have dif-
ferent phenotypes, with one family having three cases
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Table 4
Examination of OCCR
MUTATION
LOCATION
ALL FAMILIESa FAMILIES WITH x3 CANCER CASESb
No.
No. of Cancer Cases
No.
No. of Cancer Cases
Female Breast (Age
[years]) Ovarian Male Breast
Female Breast at Age
!60 Years (Age [years]) Ovarian Male Breast
OCCR 82 160 (48.0) 48 17 31 88 (44.9) 31 9
OCCR 28 103 (41.9) 14 16 21 76 (40.3) 12 15
a As defined in table 3. For age at diagnosis, ; for breast cancer versus ovarian cancer, .P ! .0001 P  .12
b As defined in table 3. For age at diagnosis, ; for breast cancer versus ovarian cancer, .P ! .0005 P  .11
of male breast cancer and four cases of female breast
cancer, a second family having three cases of ovarian
cancer, and a third family having eight site-specific cases
of female breast cancer.
By contrast, the 3034del4 mutation has been found
in families in seven different western European and
North American countries (Belgium, Canada, France,
Italy, Spain, Switzerland, and the United States). There
was a considerable amount of haplotype diversity among
the 11 families examined, accounting for the large value
of the estimated age. Although our analysis failed to find
significant statistical evidence of multiple independent
origins for this mutation (the maximum-likelihood es-
timate for the proportion due to independent mutation
is 0), given the limited number of families available for
analysis, statistically we could not rule out the possibility
that there were independent mutations for as many as
half the families. This mutation is in a region that may
be a hot spot for such deletions. Another 4-bp deletion,
located only 2 bp downstream, has been reported in five
families thus far, and a 2-bp deletion located 4 bp down-
stream has been reported once (Breast Cancer Infor-
mation Core).
Of particular interest is the 6174delT mutation found
in high frequency in the Ashkenazi Jewish population.
Along with the two BRCA1 mutations (185delAG and
5382insC), it has been estimated that 1 in 50 Ashkenazi
Jewish individuals carry one of these three mutations
(Struewing et al. 1995, 1997; Oddoux et al. 1996; Roa
et al. 1996). These mutations account for∼30%of early-
onset breast cancer (Neuhausen et al. 1996a; Offit et al.
1996; Tonin et al. 1996) and for as much as 60% of all
ovarian cancer in this population (Abeliovich et al.
1997). On the basis of our analysis of haplotypes and
genotypes of 69 families with the 6174delT mutation,
we estimate that the mutation originated ∼29 genera-
tions ago (1-LOD support interval 22–38). The corre-
sponding analysis for the age of the BRCA1 185delAG,
on the basis of our original set of 18 families with this
mutation, resulted in an estimate of 46 generations (1-
LOD support interval 22–82) and suggested that the
cases in ∼90% of the families are due to the presumed
ancestral Jewish mutation (an estimate reflecting the fact
that two families of non-Jewish ancestry were part of
the sample). Thus, the 6174delT mutation appears to
have originated more recently. Support for the more re-
cent origin of the 6174delT mutation comes from ex-
amination of these mutations in 44 non-Ashkenazi Jew-
ish patients. One Iraqi patient had a 185delAG
mutation, and none had a 6174delT mutation (Abe-
liovich et al. 1997). Sher et al. (1996) also reported a
185delAG mutation in an Iraqi Jew, suggesting that this
mutation has an origin earlier than that of the 6174delT
mutation. More recently, an additional three BRCA1
185delAG mutations have been identified, in a sample
of 639 Iraqi Jews (Bar-Sade et al. 1997), but, to our
knowledge, the 6174delT mutation has never been
found outside the Ashkenazi Jewish population.
Our analysis was consistent with the finding by Gay-
ther et al. (1997)—that is, that there is a higher incidence
of ovarian cancer relative to breast cancer associated
with the OCCR; however, this higher incidence was not
statistically significant. One possible reason for the dif-
ference between the significance presented here and that
reported by Gayther et al. (1997) could be the ill-defined
5′ end of the OCCR. The 3034del4 mutation is on the
5′ border of the OCCR, as defined by Gayther et al.
(1997), and its exclusion, rather than inclusion in the
OCCR, could have an affect on the analysis.
Among the mutations, there were significant differ-
ences associated with age at diagnosis of breast cancer.
Much of the variation was associated with mutation
location relative to the OCCR. However, when we re-
moved the cases with a 6174delT mutation, the effect
of the mutation location in the OCCR, although still
present, was not significant. The later age at onset of
breast cancer in the cases with the 6174delT mutation
could be due to ease of screening families for this com-
mon mutation. However, the age effect is still present in
those families with three or more cancer cases who
would likely be screened in any testing program, sug-
gesting that mutations within the OCCR and/or, more
specifically, the 6174delT mutation do confer a later age
at onset of breast cancer. On the basis of previous studies
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of two common mutations, there is a suggestion that
mutations in the OCCR are less penetrant for breast
cancer at a younger age. In the Icelandic studies of the
999del5 mutation, which is outside the OCCR, 28% of
Icelandic breast cancer cases of age !40 years carry this
mutation, which has a population prevalence of 0.50%.
In contrast, for the 6174delT mutation, which is within
the OCCR, 8% of Ashkenazi Jewish breast cancer cases
of age !40 years carry this mutation, which has a pop-
ulation prevalence of 1.2%. Therefore, with a prevalence
twofold higher for the 6174delT mutation, there is a
large difference, in comparison with the Icelandic mu-
tation, for age at onset of breast cancer, suggesting lower
penetrance at age !40 years.
As a first step in mutation detection, comparison of
an observed haplotype in a family examination of hap-
lotypes can be useful to identify common mutations. In
addition to this set of haplotypes for recurrent muta-
tions, we are also constructing a haplotype database of
any mutations, so that others can compare their hap-
lotypes (for further information, please contact S.L.N.).
A haplotype database of Dutch mutations is available
from a Leiden University Medical Center Department of
Human Genetics Website. Since multiple families with
identical mutations on identical genetic backgrounds can
be ascertained, this will allow us to better elucidate ad-
ditional genetic and environmental factors that contrib-
ute to the observed variation in phenotype. Similarly,
studies of families with identical mutations but with dif-
ferent origins will allow us to examine better the possible
effect of genetic modifier loci. A copy of the revised
version of the haplotype-analysis program is available,
on request, from D.E.G.
Acknowledgments
The authors wish to thank the many families who partici-
pated in the research studies described in this article. This work
was supported by U.S. Department of Defense grants DAMD-
17-94-J-4260 and DAMD 17-96-I-6266 (both to S.L.N.), by
the Canadian Breast Cancer Foundation and U.S. Department
of Defense grant DAMD-17-J-4299 (both to S.A.N.), by Na-
tional Institutes of Health grant HG-00571 (to D.G.), by Hun-
garian research grants OMFBIEU 96-09-004 and OTKA
T19307 (both to E.O.), by Spanish Ministry of Education
grant CICYT 96/0192 (to A.O. and J.B.), by National Insti-
tutes of Health grant R01 CA27632 (to E.S. and M.-C.K.), by
Swedish Cancer Society grants (to A.B.), by an Italian Asso-
ciation for Cancer Research grant (to M.A.C.), and by Cancer
Research Campaign program grants. B.A.J.P. is a Gibb Fellow
of the CRC. This work was also supported by the Utah Cancer
Registry, which is funded by National Cancer Institute contract
N01-CN-6700, with additional support from the Utah De-
partment of Health and the University of Utah. We also want
to thank clinicians and researchers at all the institutions, in-
cluding Ha˚kan Olsson, Oskar Johannsson, Niklas Loman, and
Ulf Kristoffersson from the Oncogenetic Group at University
Hospital in Sweden; and Mary Daly, Josephine Costalas, and
JoEllen Dangel from Fox Chase Cancer Center. We also thank
Thao Tran for performing the genotyping at the University of
Utah. A.O. is a fellow of the Funacio´n Conchita Ra´bago.
Electronic-Database Information
URLs for data in this article are as follows:
Breast Cancer Information Core, http://www.nchgr.hih.gov/
intramuralresearch/Labtransfer/Bic
Leiden University Medical Center Department of Human Ge-
netics (“Haplotypes carrying BRCA1 mutations found
repeatedly in the Dutch population”), http://ruly70.
medfac.leidenuniv.nl/˜devilee/hapover.htm
References
Abeliovich D, Kaduri L, Lerer I, Weinberg N, Amir G, Sagi
M, Zlotogora J, et al (1997) The founder mutations
185delAG and 5382insC in BRCA1 and 6174delT in
BRCA2 appear in 60% of ovarian cancer and 30% of early-
onset breast cancer patients among Ashkenazi women. Am
J Hum Genet 60:505–514
Bar-Sade RB, Theodor L, Gak E, Kruglikova A, Hirsch-Yech-
ezkel G, Modan B, Kuperstein G, et al (1997) Could the
185delAG BRCA1 mutation be an ancient Jewish mutation?
Eur J Hum Genet 5:413–416
Couch JF, Rommens JM, Neuhausen SL, Belanger C, Dumont
M, Abel K, Bell R, et al (1996a) Generation of an integrated
transcription map of the BRCA2 region on chromosome
13q12-q13. Genomics 36:86–92
Couch FJ, Weber BL, Breast Cancer Information Core (1996b)
Mutations and polymorphisms in the familial early-onset
breast cancer (BRCA1) gene. Hum Mutat 8:8–18
Dib C, Faure S, Fizames C, Samson D, Drouot N, Vignal A,
Millasseau P, et al (1996) A comprehensive genetic map of
the human genome based on 5,264 microsatellites. Nature
380:152–154
Gayther SA, Mangion J, Russell P, Seal S, Barfoot R, Ponder
BA, Stratton MR, et al (1997) Variation of risks of breast
and ovarian cancer associated with different germline mu-
tations of the BRCA2 gene. Nat Genet 15:103–105
Ha˚kansson S, Johannsson O, Johansson U, Sellberg G, Loman
N, Gerdes A-M, Holmberg E, et al (1997) Moderate fre-
quency of BRCA1 and BRCA2 germ-line mutations in Scan-
dinavian familial breast cancer. Am J Hum Genet 60:
1068–1078
Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman
K, Tavtigian S, Liu Q, et al (1994) Isolation of a strong
candidate for the 17q-linked breast and ovarian cancer sus-
ceptibility gene, BRCA1. Science 266:66–71
Neuhausen S, Gilewski T, Norton L, Tran T, McGuire P, Swen-
sen J, Hampel H, et al (1996a) Recurrent BRCA2 6174delT
mutations in Ashkenazi Jewish women affected by breast
cancer. Nat Genet 13:126–128
Neuhausen SL, Mazoyer S, Friedman L, Stratton M, Offit K,
Caligo A, Tomlinson G, et al (1996b) Haplotype and phe-
notype analysis of six recurrent BRCA1 mutations in 61
1388 Am. J. Hum. Genet. 62:1381–1388, 1998
families: results of an international study. Am J Hum Genet
58:271–280
Oddoux C, Struewing JP, Clayton M, Brody LC, Neuhausen
S, Kaback M, Goldgar D, et al (1996) The carrier frequency
of the BRCA2 6174delT mutation among Ashkenazi Jewish
individuals is approximately 1%. Nat Genet 14:188–190
Offit K, Gilewski T, McGuire P, Schluger A, Brown K, Neu-
hausen S, Skolnick M, et al (1996) Germline BRCA1
185delAG mutations in Jewish women affected by breast
cancer. Lancet 347:1643–1645
Roa BB, Boyd AA, Volcik K, Richards CS (1996) Ashkenazi
Jewish population frequencies for common mutations in
BRCA1 and BRCA2. Nat Genet 14:185–187
Sher C, Sharabini-Gargir L, Shohat M (1996) Breast cancer
and BRCA1 mutations. N Engl J Med 334:1199
Struewing JP, Abeliovich D, Peretz T, Avishai N, Kaback MM,
Collins FS, Brody LC (1995) The carrier frequency of the
BRCA1 185delAG mutation is approximately 1 percent in
Ashkenazi Jewish individuals. Nat Genet 11:198–200
Struewing JP, Hartage P, Wacholder S, Baker SM, Berlin M,
McAdams M, Timmerman MM, et al (1997) The risk of
cancer associated with specific mutations of BRCA1 and
BRCA2 among Ashkenazi Jews. N Engl J Med 336:
1401–1408
Szabo CI, King M-C (1997) Population genetics of BRCA1
and BRCA2. Am J Hum Genet 60:1013–1020
Tavtigian SV, Simard J, Rommens J, Shattuck-Eidens D, Couch
F, Neuhausen S, Merajver S, et al (1996) The complete
BRCA2 gene and mutations in 13q-linked kindreds. Nat
Genet 12:333–337
Tonin P, Weber B, Offit K, Couch F, Rebbeck T, Neuhausen
S, Godwin A, et al (1996) A high frequency of BRCA1 and
BRCA2 mutations in 222 Ashkenazi Jewish breast cancer
families. Nat Med 2:1179–1183
Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Manglon
J, Collins N, et al (1995) Identification of the breast cancer
susceptibility gene BRCA2. Nature 378:789–792
